Abstract
Abstract Musculoskeletal disorders remain the most common cause of physical disability in an ageing population. The importance of increased cardiovascular disease in this group is being recognized. The dramatic therapeutic impact of the cytokine specific inhibitors in the treatment of inflammatory joint disease has been balanced by the controversy over the potential cardiovascular toxicity of the newer selective Cox-2 inhibitors. Ultrasound is rapidly emerging as a valuable diagnostic tool and circulating anti-cyclical citrullinated peptide (anti-CCP) antibodies seem a promising early diagnostic and prognostic test in rheumatoid arthritis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
